Diagnosis and treatment of drug-resistant epilepsy;DIAGNOSTICO Y TRATAMIENTO DEL PACIENTE CON EPILEPSIA FARMACORRESISTENTE

Neurologia

Volumn 11, Issue 2, 1996, Pages 56-68

  Arroyo, S ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

antiepileptic drugs; drug resistant epilepsy; epilepsy surgery; treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

EPILEPSY; HUMAN; REVIEW; BRAIN; DIAGNOSTIC ERROR; DOSE RESPONSE; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY;

ANTICONVULSANTS; BRAIN; DIAGNOSTIC ERRORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; EPILEPSY; HUMANS;

EID: 0029664744     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Hauser WA, Annegers JF, Kurland AH. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991; 32: 429-445.
2. Ochoa C, Palencia R. Study of the prevalence of epilepsy among schoolchildren in Valladolid, Spain. Epilepsia 1991; 32: 791-797.
3. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729-737.
4. Thurston JH, Thurston DL, Hixon BB, Keller AJ. Prognosis in childhood epilepsy. Additional follow-up of 148 children 15 to 23 years after withdrawal of anticonvulsant therapy. N Engl J Med 1982; 306: 831-836.
5. Shinnar S, Berg AT, Moshé SL et al. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. Ann Neurol 1994; 35: 534-545.
6. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994; 44: 601-608.
7. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995; 346: 140-144.
8. Elwes RDC, Johnson AL, Shorvon SD, Reynolds EH. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944-977.
9. Rodin E, Klutke G, Chayasirisobohm S. Epileptic patients who are refractory to anticonvulsant medications. Neurology 1982; 32: 1.382-1.384.
10. Leis AA, Ross MA, Summers AK. Psychogenic seizures: Ictal characteristics and diagnostic pitfalls. Neurology 1992; 42: 95-99.
11. Pierelli F, Chatrian GE, Erdly WW, Swanson PD. Long-term EEG-video-audio monitoring: Detection of the partial epileptic seizures and psychogenic episodes by 24-hour EEG record review. Epilepsia 1989; 30: 513-523.
12. Meierkord H, Will B, Fish D, Shorvon S. The clinical features and prognosis of pseudoseizures diagnosed using video-EEG telemetry. Neurology 1991; 41: 1.643-1.646.
13. Walczak TS, Williams DT, Berten W. Utility and reliability of placebo infusion in the evaluation of patients with seizures. Neurology 1994; 44: 394-399.
14. Lancman ME, Asconape JJ, Craven WJ, Howard G, Penry JK. Predictive value of induction of psychogenic seizures by suggestion. Ann Neurol 1994; 35: 359-361.
15. Spitz MC. Panic disorder in seizure patients: a diagnostic pitfall. Epilepsia 1991; 32: 33-38.
16. Gastaut H. Syncope and seizure. Electroencephalogr Clin Neurophysiol 1958; 10: 571-572.
17. Garson A Jr, Dick M, Fournier A et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993; 87: 1.866-1.872.
18. Singh B, al Shahwan SA, Habbab MA, al Deeb SM, Biary N. Idiopathic long QT syndrome: asking the right question. Lancet 1993; 341: 741-742.
19. Gospe SM, Gabor AJ. Electroencephalography laboratory diagnosis of prolonged QT interval. Ann Neurol 1990; 28: 387-390.
20. Cramer JA, Mattson RH, Prevey M, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3.273-3.277.
21. Lesser RP, Pippenger CE, Lüders HO, Dinner DS. High-dose monotherapy in treatment of intractable seizures. Neurology 1984; 34: 707-711.
22. Kutt H, Winters W, Kokenge R, McDowell F. Diphenylhidantoin metabolisms, blood levels, and toxicity. Arch Neurol 1964; 11: 642-658.
23. Eisen AA. Peripheral nerve function in long-term therapy with diphenylhydantoin. Neurology 1974; 24: 411-417.
24. Mattson RH, Cramer JA, Collins JF et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-151.
25. Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-771.
26. Heller AJ, Chesterman P, Elwes RDC et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiat 1995; 58: 44-50.
27. Mitchell WG, Chavez JM. Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 1987; 28: 56-60.
28. Verety CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37: 97-108.
29. Brodie MJ, Yuen AWC. Lamotrigine tolerability: a view from monotherapy trials. Epilepsia 1995; 36 Supl 3: 117 [resumen].
30. Kälviäinen R, Äikiä M, Riekkinen PJ. Vigabatrin monotherapy in newly diagnosed patients with epilepsy: two-year comparative follow-up of efficacy, safety, and cognitive effects. Epilepsia 1995; 36 Supl 3: 105 [resumen].
31. Dulac O. The Lennox-Gastaut syndrome. Epilepsia 1993; 34 Supl 7: 7-17.
32. Lo WD, Donat JF, Wright FS. Tonic and myoclonic seizures in Lennox-Gastaut Syndrome mistaken as complex partial seizures. J Epilepsy 1991; 4: 211-215.
33. Bauer G, Benke T, Bohr K. The Lennox-Gastaut syndrome in adulthood. En: Niedermeyer E, Degen R, eds. The Lennox-Gastaut syndrome. Nueva York: Aan R. Liss Inc, 1988; 317-327.
34. Manonmani V, Wallace SJ. Epilepsy with myoclonic absences. Arch Dis Child 1994; 70: 288-290.
35. Sofijanov NG. Clinical evolution and prognosis of childhood epilepsies. Epilepsia 1982; 23: 61-69.
36. Hart YM, Sander JW, Johnson AL, Shorvon SD. National General Practice. Study of Epilepsy: recurrence after a first seizure. Lancet 1990; 336: 1.271-1.274.
37. Brorson LO, Wranne L. Long-term prognosis in childhood epilepsy: survival seizure prognosis. Epilepsia 1987; 24: 324-330.
38. Blanc C, Lafontaine E, Laplane R. Les activités EEG paroxystiques généralisées ou focales chez les adultes non comitiaux: Études évolutive correlations longitudinales. Rev Neurol (París) 1964; 111: 362-369.
39. Cavazzuti, Capella L, Nalin A. Longitudinal study of epileptiform EEG patterns in normal children. Epilepsia 1980; 21: 43-55.
40. Cascino GD, Jack CR Jr, Hirschorn KA, Sharbrough FW. Identification of the epileptic focus: magnetic resonance imaging. Epilepsy Research Supplement 1992; 5: 95-100.
41. Palmini A, Andermann F, Olivier A et al. Focal neuronal migration disorders and intractable partial epilepsy: a study of 30 patients. Ann Neurol 1991; 30: 741-749.
42. Lammers MW, Hekster YA, Meinardi H, Renier WO, Van Lier H. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995; 36: 440-446.
43. Schmidt D, Richter K. Alternative single anticonvulsant drug therapy for refractory epilepsy. Ann Neurol 1986; 19: 85-87.
44. Morris JC, Dodson WE, Hatlelid JM, Ferrandelli JA. Phenytoin and carbamazepine alone and in combination: anticonvulsant and neurotoxic effects. Neurology 1987; 37: 1.111-1.118.
45. Leppik IE, Sherwin AL. Anticonvulsant activity of phenobarbital and phenytoin in combination. J Pharmacol Exp Ther 1977; 200: 570-575.
46. Bourgeois BFD, Wad N. Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity. Epilepsia 1988; 29: 482-487.
47. Bourgenois BF. Pharmacologic intervention and treatment of childhood seizure disorders: relative efficacy and safety of antiepileptic drugs. Epilepsia 1994; 35 Supl 2: 18-23.
48. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Safety 1993; 9: 156-184.
49. Liu H, Delgado MR, Browne RH. Interactions of valproic acid with carbamazepine and its metabolites concentrations, concentration ratios, and level/dose in epileptic children. Clin Neuropharmacol 1995; 18: 1-12.
50. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy. Epilepsia 1981; 22: 1-10.
51. Schmidt S. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. J Neurol Neurosurg Psychiatry 1982; 45: 1.119-1.124.
52. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983; 24: 368-376.
53. Albright P, Bruni J. Reduction of polypharmacy in epileptic patients. Arch Neurol 1995; 42: 797-799.
54. Kutt H, Solomon G, Wasterlain C, Peterson H, Louis S, Carruthers R. Carbamazepine in difficult to control epileptic outpatients. Acta Neurol Scand supl 1977; 75 Supl 60: 27-32.
55. Gallagher BB, Baumel IP, Woodbury SG, Dimicco JA. Clinical evaluation of eterobarb, a new anticonvulsant drug. Neurology 1975; 25: 399-404.
56. Lorenzo NY, Bromfield EB, Theodore WH. Carbamazepine and phenytoin: combination versus single drug therapy. Eur J Neurol 1995; 2: 101-105.
57. Theodore WH, Porter RJ. Removal of sedative-hypnotic antiepileptic drugs from the regimens of patients with intractable epilepsy. Ann Neurol 1983; 13: 320-324.
58. Bourgeois BFD. Childhood epilepsy: pharmacological considerations. Acta Neurol Scand 1992; 140: 23-27.
59. Trimble MR, Clobazam. En: Resor SR Jr, Kutt H, eds. The medical treatment of epilepsy. Nueva York: Marcel Dekker, Inc., 1992; 319-328.
60. Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia 1982; 23: 531-544.
61. Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1992; 14: 269-274.
62. Sobaniec W. Certain aspects of interaction between sodium valproate and other anticonvulsant drugs in the therapy of epilepsy in children. Mater Med Pol 1992; 24: 115-119.
63. Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SSM. Clobazam as adjuntive treatment in refractory epilepsy. Br Med J 1983; 286: 1.246-1.247.
64. Heller AJ, Ring HA, Reynolds EG. Factors relating to dramatic response to clobazam therapy in refractory epilepsy. Epilepsy Res 1988; 2: 276-278.
65. Cereghino JJ. Clinical trial design for antiepileptic drugs. Ann Neurol 1992; 32: 393-394.
66. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476-479.
67. Kälviäinen R, Äikiä M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arch Neurol 1995; 52: 989-996.
68. Arteaga R, Herranz JL, Valdizan EM, Armijo JA. Gamma-vinyl GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children. Epilepsia 1992; 33: 923-931.
69. Rey E, Pons G, Olivé G. Vigabatrin. Clinical pharmacokinetics [review]. Clin Pharmacokinet 1992; 23: 267-278.
70. Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res 1993; 16: 89-98.
71. Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN. Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 1993; 244: 293-301.
72. Kondo T, Fromm GH, Schmidt B. Comparison of gabapentin with other antiepileptic and GABAergic drugs. Epilepsy Res 1991; 8: 226-231.
73. Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993; 20: 297-301.
74. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992; 13: 107-112.
75. Herranz JL, Arteaga R, Armijo JA. Nuevos antiepilépticos: vigabatrina, lamotrigina y felbamato. Neurología 1994; 410-417.
76. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs [Review]. Clin Pharmacokinet 1993; 24: 441-452.
77. Betts T, Goodwin G, Withers RM, Yuen AW. Human safety of lamotrigine. Epilepsia 1991; 32: Supl 2: 17-21.
78. Cocito L, Maffini M, Loeb C. Vigabatrin in chronic epilepsy: a 7-year follow-up study of responder patients. Seizure 1993; 2: 301-307.
79. Martin PJ, Millac PA. Vigabatrin: a three year clinical analysis. Seizure 1993; 2: 137-140.
80. Cocito L. Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res 1994; 19: 123-127.
81. Lhoir A. Vigabatrin in uncontrolled seizures: Belgian clinical experience. The Belgian Vigabatrin Evaluation Group. Clin Neurol Neurosurg 1994; 96: 42-46.
82. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM. Effects of differing dosages of vigabatrin (Sabril) cognitive abilities and quality of life in epileptics. Epilepsia 1995; 36: 164-173.
83. Messenheimer J, Ramsay RE, Willmore LJ et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994; 35: 113-121.
84. Matsuo F, Bergen D, Faught E et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43: 2.284-2.291.
85. Rimmer EM, Richens A. Double-blind study of gammavinyl GABA in patients with refractory epilepsy. Lancet 1984; 1: 189-190.
86. Gram L, Klosterskov P, Dam M. Gamma-vinyl GABA: A double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985; 17: 262-266.
87. Schapel GJ, Beran RG, Vajda FJ et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993; 56: 448-453.
88. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: A double blind, placebo-controlled, parallel-group study. Neurology 1993; 43:2.292-2.298.
89. Reynolds EH, Ring HA, Farr IN, Heller AJ, Elwes RD. Open, double-blind and long-term study of vigabatrin in chronic epilepsy. Epilepsia 1991; 32: 530-538.
90. Anonymous. Gabapentin in partial epilepsy. UK Gabapentin Study Group. Lancet 1990; 335: 1.114-1.117.
91. Loiseau P, Yuen AW, Duche B, Meneger T, Arne-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990; 7: 136-145.
92. Sander JW, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990; 6: 221-226.
93. Anhut H, Ashman P, Feuerstein TJ et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994; 35: 795-801.
94. Armijo JA, Arteaga R, Valdizan EM, Herranz JL. Coadministration of vigabatrin and valproate in children with refractory epilepsy. Clin Neuropharmacol 1992; 15: 459-469.
95. Amhut H, Greiner M, Möckel V, Murray G. Gabapentin (Neurontin) as monotherapy in newly diagnosed patients with partial epilepsy. Epilepsia 1995; 36 Supl 3: 119.
96. Hayes A, Garofalo E, Mann M et al. Gabapentin (Neurontin) monotherapy in patients with medically refractory partial seizures: An open-label extension study. Epilepsia 1995; 36 Supl 3: 119 [resumen].
97. Severi S, Bianchi A, Zolo P, Muscas GC. Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia 1995; 36 Supl 3: 113-114.
98. Roger J, Rémy C, Bureau M et al. Le syndrome de Lennox-Gastaut de l'adulte. Rev Neurol (París) 1987; 143: 401-405.
99. Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol 1993; 9: 465-569.
100. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990; 17: 317-319.
101. Battino D, Buti D, Croci D et al. Lamotrigine in resistant childhood epilepsy. Neuropediatrics 1993; 24: 332-336.
102. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992; 32: 305-307.
103. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359-367.
104. Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993; 34 Supl 7: 18-24.
105. Pennell PB, Ogaily M, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995; 45: 456-460.
106. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia 1989; 30: 430-437.
107. Feucht M, Brantner-Inhaler S. Gamma-vinyl-GABA (Vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia 1994; 35: 993-998.
108. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983; 33: 1.487-1.489.
109. Browne TR, Mattson RH, Penry JK et al. Vigabatrin for refractory complex partial seizures: Multicenter single-blind study with long-term follow-up. Neurology 1987; 37: 184-189.
110. Kanner AM, Kaydanova Y, de Toledo-Morrell L et al. Tailored anterior temporal lobectomy. Relation between extent of resection of mesial structures and postsurgical seizures outcome. Arch Neurol 1995; 52: 173-178.
111. Hori T, Tobuchi S, Kurosaki M, Kondo S, Takenobu A, Watanabe T. Subtemporal amygdalohippocampectomy for treating medically intractable temporal lobe epilepsy. Neurosurgery 1993; 33: 50-57.
112. Erba G, Winston KR, Adler JR, Welch K, Ziegler R, Hornig GW. Temporal lobectomy for complex partial seizures that began in childhood. Surg Neurol 1992; 38: 424-432.
113. Goldring S, Edwards I, Harding GW, Bernardo KL. Results of anterior temporal lobectomy that spares the amygdala in patients with complex partial seizures. J Neurosurgery 1992; 77: 185-193.
114. Cascino GD, Sharbrough FW, Hirschorn KA, Marsh WR. Surgery for focal epilepsy in the older patient. Neurology 1991; 41: 1.415-1.417.
115. Elwes RD, Dunn G, Binnie CD, Polkey CE. Outcome following resective surgery for temporal lobe epilepsy: a prospective follow up study of 102 consecutive cases. J Neurol Neurosurg Psychiat 1991; 54: 949-952.
116. Guldvog B, Lyning Y, Hauglie-Hanssen E, Flood S, Bjrnaes H. Surgical versus medical treatment for epilepsy. I. Outcome related to survival, seizures, and neurologic deficit. Epilepsia 1991; 32: 375-388.
117. Hajek M, Wieser HG. Extratemporal, mainly frontal, epilepsies: Surgical results. J Epilepsy 1988; 1: 103-109.
118. Adler J, Erba G, Winston KR, Welch K, Lombroso CT. Results of surgery for extratemporal partial epilepsy that began in childhood. Arch Neurol 1991; 48: 133-140.
119. Laskowitz DT, Sperling MR, French JA, Oconnor MJ. The syndrome of frontal lobe epilepsy: characteristics and surgical management. Neurology 1995; 45: 780-787.
120. Slater NT, Andermann F, Rasmussen T, Oliver A, Quesney LF. Parietal lobe epilepsy. Clinical manifestations and outcome in 82 patients treated surgically between 1929 and 1988. Brain 1995; 118: 607-627.
121. Cascino GD, Hulihan JF, Sharbrough FW, Kelly PJ. Parietal lobe lesional epilepsy: electroclinical correlation and operative outcome. Epilepsia 1993; 34: 522-527.
122. Jensen I. Temporal lobe surgery around the world. Results, complications, and mortality. Acta Neurol Scand 1975; 52: 354-373.
123. Hermann BP, Seidenberg M, Haitiner A, Wyler AR. Relationship of age at onset, chronologic age, and adequacy of preoperative performance to verbal memory change after anterior temporal lobectomy. Epilepsia 1995; 36: 137-145.
124. Loring DW, Meador KJ, Lee GP. Effects of temporal lobectomy on generative fluency and other language functions. Arch Clin Neuropsychol 1994; 9: 138-229.
125. Saas K, Westerbeld M, Buchanan CP, Spencer SS, Kim JH, Spencer DD. Degree of hippocampal neuron loss determines severity of verbal memory decrease after left anteomesiotemporal lobectomy. Epilepsia 1994; 35: 1.179-1.186.
126. Lesser RP, Webber RS, Fisher RS. Design principles for computerized EEG monitoring. Electroencephalogr Clin Neurophysiol 1992; 82: 239-247.
127. Markand ON, Salanova V, Worth RM, Park HM, Wellman HH. Ictal brain imaging in presurgical evaluation of patients with medically intractable complex partial seizures. Acta Neurol Scand Supl 1994; 152: 137-144.
128. Duncan R, Patternson J, Roberts R, Hadley DM, Bone I. Ictal/postictal SPECT in the presurgical localisation of complex partial seizures. J Neurol Neurosurg Psychiat 1993; 56: 141-148.
129. Holman BL, Devous MD. Functional brain SPECT: The emergence of a powerful clinical method. J Nucl Med 1992; 33: 1.888-1.904.
130. Gaillard WD, Bhatia S, Bookheimer SY, Fazilat S, Sato S, Theodore WH. FDG-PET and volumetric MRI in the evaluation of patients with partial epilepsy. Neurology 1995; 45: 123-126.
131. Spencer SS. The relative contributions of MRI, SPECT, and PET imaging in epilepsy. Epilepsia 1994; 35 Supl 6: 72-89.
132. Theodore WH, Sato S, Kufta C, Balish MB, Bromfield EB, Leiderman DB. Temporal lobectomy for uncontrolled seizures: the role of positron emission tomography. Ann Neurol 1992; 32: 789-794.
133. Arroyo S, Lesser RP, Awad CA, Goldring S, Sutherling WW, Resnick TJ. Subdural and epidural grids and strips. In: Engel J Jr. ed. Surgical Treatment of the Epilepsies. 2nd ed. Nueva York: Raven Press, 1993; 377-386.
134. Thadani VM, Williamson PD, Berger R et al. Successful epilepsy surgery without intracranial EEG recording: criteria for patient selection. Epilepsia 1995; 36: 7-15.
135. Spencer SS, Guimaraes P, Katz A, Kim J, Spencer DD. Morphological patterns of seizures recorded intracranially. Epilepsia 1992; 33: 537-545.
136. Chung MY, Walczak TS, Lewis DV, Dawson DV, Radtke R. Temporal lobectomy and independent bitemporal interictal activity: What degree of lateralization is sufficient? Epilepsia 1991; 32: 195-201.
137. Engel J Jr, Van Ness PC, Rasmussen TB, Ojemann LM. Outcome with respect to epileptic seizures. In: Engel J Jr. ed. Surgical Treatment of the Epilepsies. 2nd ed. Nueva York: Raven Press, 1993; 609-621.
138. Adler J, Erba G, Winston KR, Welch K, Lombroso CT. Results of surgery for extratemporal partial epilepsy that began in childhood. Arch Neurol 1991; 48: 133-140.
139. Cereghino JJ. Clinical trial design for antiepileptic drugs. Ann Neurol 1992; 32: 393-394.
140. Cramer JA, Mattson RH, Prevey M, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3.273-3.277.
141. Elwes RD, Dunn G, Binnie CD, Polkey CE. Outcome following resective surgery for temporal lobe epilepsy: a prospective follow up study of 102 consecutive cases. J Neurol Neurosurg Psychiat 1991; 54: 949-952.
142. Engel J Jr, Van Ness PC, Rasmussen TB, Ojemann LM. Outcome with respect to epileptic seizures. En: Engel J Jr, ed. Surgical treatment of the epilepsies. Nueva York: Raven Press, 1993; 609-621.
143. Herranz, JL, Arteaga R, Armijo JA. Nuevos antiepilépticos: vigabatrina, lamotrigina y felbamato. Neurología 1994; 410-417.
144. Lesser RP, Pippenger CE, Lüders HO, Dinner DS. High-dose monotherapy in treatment of intractable seizures. Neurology 1984; 34: 707-711.
145. Matsuo F, Bergen D, Faught E et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43: 2.284-2.291.
146. Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-771.
147. Mattson RH, Cramer JA, Collins JF et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-151.
148. Upton N. Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. Trends Pharmacol Sci 1994; 15: 456-463.
149. Rimmer EM, Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 1984; 1: 189-190.
150. Schmidt S. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. J Neurol Neurosurg Psychiatry 1982; 45:1.119-1.124.
151. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983; 24: 368-376.
152. Theodore WH, Porter RJ. Removal of sedative-hypnotic antiepileptic drugs from the regimens of patients with intractable epilepsy. Ann Neurol 1983; 13: 320-324.
153. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: A double blind, placebo-controlled, parallel-group study. Neurology 1993; 43: 2.292-2.298.